Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.804
+0.086 (11.92%)
Dec 26, 2024, 2:04 PM EST - Market open
Ocugen Revenue
Ocugen had revenue of $1.14M in the quarter ending September 30, 2024, a decrease of -69.29%. This brings the company's revenue in the last twelve months to $4.70M, down -33.94% year-over-year. In the year 2023, Ocugen had annual revenue of $6.04M with 142.60% growth.
Revenue (ttm)
$4.70M
Revenue Growth
-33.94%
P/S Ratio
40.10
Revenue / Employee
$72,308
Employees
65
Market Cap
234.16M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MacroGenics | 141.33M |
Biodesix | 65.56M |
SOPHiA GENETICS | 64.49M |
Utah Medical Products | 44.08M |
Inventiva | 20.65M |
Profound Medical | 8.98M |
Inhibrx Biosciences | 1.57M |
Atai Life Sciences | 331.00K |
OCGN News
- 7 days ago - Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 15 days ago - Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - GlobeNewsWire
- 4 weeks ago - Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference - GlobeNewsWire
- 5 weeks ago - Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease - GlobeNewsWire
- 5 weeks ago - Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 6 weeks ago - Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Ocugen Provides Business Update with Third Quarter 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Ocugen Secures $30 Million in Debt Funding - GlobeNewsWire